AVEO commences AV-203 Phase 1 study in advanced solid tumors
Comments (0)Posts tagged: commences
Comments (0)NanoString commences second clinical study of PAM50-based breast cancer assay
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the initiation of the second clinical validation study of its PAM50-based breast cancer assay.
Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM
Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced ...
CSL Behring commences C1-INH phase I/II study in hereditary angioedema
CSL Behring announced today that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema.
angioedema, behring, commences, csl, hereditary, iii, inh, phase
Generon commences F-627 Phase II trial in breast cancer
Generon Corporation Ltd. today announced the initiation of a Phase II clinical trial for F-627 after US FDA regulatory clearance. The current study is a Phase II, randomized, multicenter, open-label, active-controlled trial of F-627 in women with breast cancer receiving myelotoxic chemotherapy.
Gilead commences GS-1101 Phase 3 trial in CLL
Gilead Sciences, Inc. today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.
Pharmanest commences SHACT Phase I pharmacokinetic study
Karolinska Development: Pharmanest AB today announced that the first patient has been dosed in an open label pharmacokinetic study with its drug candidate SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion.
CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.
ImmunoGen commences IMGN529 Phase I trial in NHL
ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.
AcelRx commences dosing in second ARX-01 Phase 3 clinical trial for acute post-operative pain
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug ...
Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain
Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.
ImmunoGen commences IMGN901 Phase II evaluation for SCLC
ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.